Insomnia News and Research

Latest Insomnia News and Research

Rotigotine provides clinically relevant improvements in RLS symptoms: Study

UCB today announced the results of a 6-month, randomized, double-blind, placebo-controlled clinical study, published in the journal Movement Disorders, showing that Neupro® (rotigotine transdermal system, 2 and 3 mg/24 hours) provided sustained, clinically relevant improvements in symptoms of Restless Legs Syndrome (RLS). The study also showed high rates of complete remission seen with rotigotine 2 mg or 3 mg/24 hours.

29 Jul 2010

Survey provides insight on roles, responsibilities for improved, sustainable workplace health

Employers should be active partners in the overall health of their employees and can play a strong role by encouraging them to take responsibility for their own health. While the thirteenth edition of The sanofi-aventis Healthcare Survey suggests that no employer or employee would dispute the return-on-investment from benefit plans such as prescription drugs, dental care, or employee assistance programs, improved and sustainable health in the workplace can only be achieved by a deeper commitment to early disease detection, preventative care, and wellness in general.

28 Jul 2010

Studies reveal impact and spread of CVBDs worldwide

Fascinating studies giving new insights into the spread of leishmaniosis in the UK and France, the appearance of new CVBDs in Germany, the state of heartworm infection in Korea and the neurological impact on humans of long-term bartonella infection from the USA are among the papers now available for download from http://www.cvbd.org, as the proceedings of the 5th Annual Canine Vector Borne Disease (CVBD) World Forum are made available online today.

28 Jul 2010

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Merck announced a non-exclusive license agreement with Laboratory Corporation of America Holdings for the commercialization of a genetic test that may help predict the response of patients with Hepatitis C virus infection to peginterferon alpha-based therapy.

28 Jul 2010

Need for better understanding of appropriate treatment choices for children with insomnia: Study

A new survey of child psychiatrists indicates that insomnia is a major problem among children in mental health treatment and at least a quarter of these patients are given sleep medication. The results of the survey, conducted by Judith Owens, MD, a sleep expert with Hasbro Children's Hospital, and colleagues, suggests that management of insomnia in this population is a common practice, although the clinical approach varies widely. The study is published in the August 2010 edition of Sleep Medicine.

27 Jul 2010

Alexza second-quarter net loss decreases to $12.9 million

Alexza Pharmaceuticals, Inc. today reported financial results for the quarter ended June 30, 2010 and provided a business update. The net loss for the three and six months ended June 30, 2010, as reported in accordance with accounting principles generally accepted in the United States (GAAP), was $12.9 million and $26.3 million, respectively, compared to a net loss of $17.0 million and $23.9 million in the respective comparable periods in 2009. Alexza had consolidated cash, cash equivalents and marketable securities at June 30, 2010 of $41.7 million.

27 Jul 2010

Somaxon's Silenor Phase 3 clinical data accepted for publication in Sleep, Sleep Medicine journals

Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced that detailed results from two Phase 3 clinical trials of the company's product Silenor® (doxepin) have been accepted for publication in peer-reviewed scientific journals.

22 Jul 2010

Herbal dietary supplements may contain toxic metals

Millions of people are taking herbs and other plant-based dietary supplements to improve their health, but they have precious little information on the actual effectiveness or potential ill effects of these products. That's the topic of an article in the current issue of Chemical & Engineering News weekly newsmagazine.

22 Jul 2010

Gladstone Institutes, H. Lundbeck collaborate to identify therapeutic candidates for neurological diseases

The Gladstone Institutes and the international pharmaceutical company H. Lundbeck A/S have announced a collaborative research agreement to study and identify therapeutic candidates for neurological diseases. The agreement funds research at the Gladstone Center for Translational Research led by Gladstone investigator Katerina Akassoglou, PhD, and establishes the new Lundbeck Center for Neurovascular and Immuno-imaging at the Gladstone Institute of Neurological Disease.

22 Jul 2010

Phase 3 study: Tapentadol ER lowers incidence of gastrointestinal adverse events

A Phase 3 open-label study, recently published online by Pain Practice, has compared tapentadol extended release tablets, an investigational pain medication, to an existing prescription pain medication, oxycodone controlled release tablets.

20 Jul 2010

ACTOS offers safety profile regarding risk of CV events in people with type 2 diabetes: Takeda

The U.S. Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee held a joint meeting primarily focused on reviewing the cardiovascular safety of rosiglitazone, as presented by the FDA and GlaxoSmithKline. Following this two day discussion, Takeda Pharmaceuticals North America, Inc. ("Takeda") underscores its position that ACTOS (pioglitazone HCl) offers an established safety profile regarding the risk of CV events in people living with type 2 diabetes.

16 Jul 2010

Drugs taken for common medical conditions cause long term cognitive impairment in older adults: Study

Drugs commonly taken for a variety of common medical conditions including insomnia, allergies, or incontinence negatively affect the brain causing long term cognitive impairment in older African-Americans, according to a study appearing in the July 13, 2010 print issue of Neurology, the medical journal of the American Academy of Neurology.

14 Jul 2010

Tart cherry juice could help reduce severity of insomnia in older adults: Study

Drinking tart cherry juice daily could help reduce the severity of insomnia and time spent awake after going to sleep, according to a new study published in the Journal of Medicinal Food.

13 Jul 2010

Reducing chronic pain, dry mouth could improve quality of life in head and neck cancer patients: Study

Head and neck cancer patients who reported poor sleep quality one year after diagnosis had more symptoms of chronic pain and complaints of dry mouth related to radiation treatments, according to a recent study from the University of Michigan Comprehensive Cancer Center.

12 Jul 2010

Shire receives FDA approval of Daytrana for ADHD in adolescents

Shire plc, the global specialty biopharmaceutical company, announced the US Food and Drug Administration (FDA) approval of Daytrana® (methylphenidate transdermal system) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents aged 13 to 17 years. Daytrana, the first and only transdermal ADHD patch, is already an FDA-approved ADHD treatment for children 6 to 12 years. Daytrana is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, and social).

7 Jul 2010

PuraMed BioScience completes clinical study of LipiGesic M for treating acute migraine

PuraMed BioScience, announced today that a clinical study of LipiGesic M has been completed. The study design was a double blind, placebo controlled, multi-site study measuring the effectiveness of LipiGesic™ M for the treatment of acute migraine attacks. The next steps include completion of the manuscript, submission for publication in a peer-reviewed medical journal and actual publication. In an effort to maximize the potential for publication, an embargo has been placed on the disclosure of any of the results of this study.

7 Jul 2010

EC approves change in posology of Circadin from 3 weeks to 3 months of treatment

Neurim Pharmaceuticals confirmed today that the European Commission (EC) has approved a change in treatment duration with Circadin from 3 to 13 weeks (3 months). Circadin is indicated for the treatment of primary insomnia in patients who are aged 55 or over.

6 Jul 2010

Chelsea reports positive outcome from DMC review of droxidopa Phase II trial in fibromyalgia

Chelsea Therapeutics International, Ltd. announced the completion and favorable outcome of an independent Data Monitoring Committee (DMC) review of the safety and efficacy data from approximately half the target enrollment in Chelsea's Phase II trial of droxidopa in fibromyalgia.

2 Jul 2010

AstraZeneca announces new support program for patients on ARIMIDEX

AstraZeneca today announced a new patient support program for postmenopausal women with hormone receptor-positive early breast cancer who are prescribed ARIMIDEX. The program is designed to provide eligible patients with instant discounts, potentially saving the patient up to $300.

1 Jul 2010

Forest Laboratories, Gedeon Richter report positive results from radiprodil Phase II study for DPNP pain

Forest Laboratories, Inc. and Gedeon Richter Plc. today announced top-line results from a Phase II placebo and positive comparator-controlled, parallel-arm, double-blind, dose-response clinical trial of the novel, investigational NR2B-selective NMDA (N-methyl D-aspartate) receptor antagonist, radiprodil (RGH-896), for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPNP).

29 Jun 2010

Insomnia News and Research

Latest Insomnia News and Research

Rotigotine provides clinically relevant improvements in RLS symptoms: Study

Survey provides insight on roles, responsibilities for improved, sustainable workplace health

Studies reveal impact and spread of CVBDs worldwide

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Need for better understanding of appropriate treatment choices for children with insomnia: Study

Alexza second-quarter net loss decreases to $12.9 million

Somaxon's Silenor Phase 3 clinical data accepted for publication in Sleep, Sleep Medicine journals

Herbal dietary supplements may contain toxic metals

Gladstone Institutes, H. Lundbeck collaborate to identify therapeutic candidates for neurological diseases

Phase 3 study: Tapentadol ER lowers incidence of gastrointestinal adverse events

ACTOS offers safety profile regarding risk of CV events in people with type 2 diabetes: Takeda

Drugs taken for common medical conditions cause long term cognitive impairment in older adults: Study

Tart cherry juice could help reduce severity of insomnia in older adults: Study

Reducing chronic pain, dry mouth could improve quality of life in head and neck cancer patients: Study

Shire receives FDA approval of Daytrana for ADHD in adolescents

PuraMed BioScience completes clinical study of LipiGesic M for treating acute migraine

EC approves change in posology of Circadin from 3 weeks to 3 months of treatment

Chelsea reports positive outcome from DMC review of droxidopa Phase II trial in fibromyalgia

AstraZeneca announces new support program for patients on ARIMIDEX

Forest Laboratories, Gedeon Richter report positive results from radiprodil Phase II study for DPNP pain

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Insomnia News and Research

Latest Insomnia News and Research

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in